Given that SESN2 is greatly implicated in protecting cancer cells from apoptosis and promoting cell survival via AKT and AMPK, we hypothesized that it might confer primary resistance to sorafenib by activating AKT and AMPK in HCC. This evidence concerns the gene AKT1 and hepatocellular carcinoma.